TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01491035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 5 mg tablets for 14 days; orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 5 mg tablets for 14 days; orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
Study: NCT01414751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Absolute risk reduction
Description: Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolongation of life
Description: Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
Study: NCT01144000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
Study: NCT01511133

Intervention type: PROCEDURE
Intervention: Stool sample
Description: Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.

Intervention type: PROCEDURE
Intervention: Stool sample
Description: Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
Study: NCT01276704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains same filler materials as commercially available Brevail® but without active SDG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secoisolariciresinol
Description: 1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
Study: NCT03913182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: 500mg po Qd
Study: NCT03987919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered SC
Study: NCT01594333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
Study: NCT02106260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS003
Study: NCT02154178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker group
Description: use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
Study: NCT00594659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Nine session treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Psychotherapy
Description: Nine session computer delivered treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational enhancement therapy
Description: Two session treatment
Study: NCT03298867

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Teprotumumab
Description: Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
Study: NCT04307199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane sweep
Description: Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane sweep
Description: Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane sweep
Description: Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane sweep
Description: Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
Study: NCT02016352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: patient CSF extraction with hydrocephalus
Description: CSF extraction

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: witness CSF extraction
Description: CSF extraction from patient not suffering from hydrocephalus
Study: NCT03432403

Intervention type: DEVICE
Intervention: Ambu LMA
Description: Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured

Intervention type: DEVICE
Intervention: Gastro LMA
Description: Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
Study: NCT03830658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Intervention on Self-care with AVF (SISC-AVF)
Description: Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Intervention on Self-care with AVF (SISC-AVF)
Description: Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions.
Study: NCT02843217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle, screening
Study: NCT03117023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
Study: NCT04261465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP INHIBITOR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study: NCT03298867

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
Study: NCT03873974

Intervention type: DIAGNOSTIC_TEST
Intervention: DualDur dark-field microscopic test
Description: Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: DualDur dark-field microscopic test
Description: Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: DualDur dark-field automatic microscopic test
Description: Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: DualDur dark-field automatic microscopic test
Description: Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Western blot IgM and IgG
Description: Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Western blot IgM and IgG
Description: Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bózsik Western blot IgM and IgG
Description: Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bózsik Western blot IgM and IgG
Description: Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: enzyme-linked immunosorbent assay (ELISA) IgM and IgG
Description: Standard ELISA test for Lyme borreliosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: enzyme-linked immunosorbent assay (ELISA) IgM and IgG
Description: Standard ELISA test for Lyme borreliosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: DualDur Polymerase chain reaction
Description: DualDur PCR test for Lyme borreliosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: DualDur Polymerase chain reaction
Description: DualDur PCR test for Lyme borreliosis.
Study: NCT01132430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Brief MI 3x30 minute sessions within 4-6 week period

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard medical care within 4-6 week period
Study: NCT00873912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza virus vaccine
Description: Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
Study: NCT04261465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study: NCT03555214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy based on soft tissues
Description: Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy based on structural techniques
Description: Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy based on soft tissues and structural techniques
Description: Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique.
Study: NCT04038814

Intervention type: PROCEDURE
Intervention: Routine prevention of VAP
Description: Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax

Intervention type: PROCEDURE
Intervention: Modified prevention of VAP
Description: 3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage
Study: NCT02731755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat
Description: The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 60g cream of rice
Study: NCT03364595

Intervention type: PROCEDURE
Intervention: plate fixation
Description: ORIF of the radial head fracture

Intervention type: PROCEDURE
Intervention: replacement
Description: replacement of the radial head fracture
Study: NCT00423098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate sodium
Description: Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
Study: NCT06123871

Intervention type: OTHER
Intervention: Grouping based on previous laboratory results, no intervention.
Description: The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken

Intervention type: OTHER
Intervention: Grouping based on previous laboratory results, no intervention.
Description: The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
Study: NCT02284555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
Study: NCT03786991

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04616963

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine Tenofovir Alafenamide 200/25 mg
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
Study: NCT00566514

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-ribose
Description: 5 grams administered orally TID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: 5 grams orally TID
Study: NCT02474394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mcgrath
Description: The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
Study: NCT01016522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoCal
Description: Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
Study: NCT02180763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammanorm
Description: Sub-Q IgG
Study: NCT01489982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box (Litebook company)
Description: Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and sleep hygiene
Description: 6 weekly sessions totalling 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin and Zopiclone
Description: Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light box ( Litebook company)
Description: The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
Study: NCT01751958

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Description: Epidural steroid injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Description: Epidural steroid injection
Study: NCT01594333

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week